Mochida Pharmaceutical Co.,Ltd. [4534.T]
TOKYO, Mar 30 (Pulse News Wire) – Mochida Pharmaceutical CO.,LTD. (4534.T) announced today that its board of directors, held, resolved to repurchase up to 148 billion yen worth of its own shares.
The decision was made to mitigate the impact of share issuance on stock supply, enhance shareholder returns, and improve capital efficiency. The company plans to acquire up to 14,800,000 shares, representing approximately 1.48% of outstanding shares excluding treasury stocks. The repurchase will take place through open-market purchases on the Tokyo Stock Exchange from April 18, 2026, to December 18, 2026.
However, due to market conditions, some or all of the planned repurchases may not occur. As of December 18, 2026, the company had 940,273 treasury shares out of a total of 1,000,000,000 outstanding shares excluding treasury stocks. The move reflects the company's commitment to expanding its shareholder base and enhancing liquidity while maintaining flexibility in its capital management strategy.
🟢 Confidence: High AI-translated content.